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Background
Cardiac failure in septic shock usually originates from
hypovolaemia, impaired global contractility or right ven-
tricular failure (RVF). Acute RVF due to endotoxin-
mediated pulmonary hypertension results in global
hypoperfusion. However, the treatment of pulmonary
vascular resistance (PVR) in septic patients remains a
black box.
Methods
After ethical approval, septic shock was induced in 32
pigs ( 25 ± 3 kg) by continuous infusion of endotoxin
(Escherichia coli serotype 0111:B4). The animals
received a protocol-based treatment with fluids and
vasopressors according to the surviving sepsis campaign
guidelines. Then, they were randomized to either
inhaled (i.h.) (240μg kg-1) or intravenous (i.v.) (24μg kg-
1) treatment with BAY 41-8543 or controls. Heart rate
(HR (bpm)), mean arterial pressure (MAP (mmHg)),
mean pulmonary artery pressure (MPAP (mmHg)), car-
diac output (CO (l min-1)) and PVR (dyn sec cm-5) were
assessed every 15 minutes for 1 h after starting the
treatment. Following a wash out period of 1 h, the ani-
mals were once more randomized to double dose (D2) i.
h. or i.v. respectively or to simultaneous administration
of Bay 41-8543 at a single dose together with NO (i.h.)
at 20 ppm. Hemodynamic measurements were taken for
another hour. Data are expressed as mean ± SD at
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* p<0.05 **p<0.01 vs. control group (con)
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shock and 30 minutes after treatment. Differences
between groups were analyzed using a linear mixed-
effects model.
Results
Both during i.h. and i.v. application of BAY 41-8543, a
significant decrease in PVR and an increase in CO was
observed. Additive inhaled NO decreased PVR more
than doubling the dose of BAY 41-8543 (Table 1).
Conclusion
The stimulator of the soluble guanylate cyclase BAY 41-
8543 offers a treatment option for pulmonary hyperten-
sion in septic shock. Both inhalative and intravenous
administration of BAY 41-8543 reduces PVR and
increase CO. Further, there seems to be an additive
effect of inhaled NO.
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